Current antioxidant therapies targeting reactive oxygen species (ROS) are often hindered by limitations in stability, efficacy, dosage tolerance, biocompatibility, or immunogenicity. To address these challenges, we developed a therapeutic platform...
Zhang et al. (Thu,) studied this question.